免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
原发黑色素瘤或治疗前转移灶的 H&E 染色切片上的 TIL 评分与 3 级或以上 irAEs 的发生无关。
TIL(肿瘤浸润淋巴细胞)能否预测免疫相关不良事件(irAE)尚不明确,尽管已有研究提示肿瘤免疫原性可能与irAE相关。本研究考察治疗前原发灶及转移灶标本中的TIL丰度与随后发生严重irAE之间的关系。
研究者回顾性纳入荷兰10家医院接受一线抗程序性细胞死亡蛋白1(PD-1)单药或联合抗细胞毒性T淋巴细胞相关蛋白4(CTLA-4)治疗的晚期皮肤黑色素瘤患者。根据原发黑色素瘤及治疗前转移灶代表性苏木精-伊红(H&E)染色切片,将TIL评分为“缺如”“非活跃”或“活跃”。采用单变量逻辑回归评估TIL评分与严重irAE发生的关系,并用Fine-Gray亚分布风险模型估算严重irAE的累积发生率。
1346例符合条件的患者中,536例有原发黑色素瘤标本,613例有转移灶标本。抗PD-1治疗患者中15%发生严重irAE,抗PD-1联合抗CTLA-4治疗患者中为49%。原发黑色素瘤或治疗前转移灶标本中存在TIL,均与3级irAE发生无关(分别P=0.70和P=0.91)。单变量分析显示,与TIL缺如患者相比,TIL活跃患者发生严重irAE的概率并未升高:原发灶标本OR为1.15(95%置信区间0.60–2.18),转移灶标本OR为0.77(95%置信区间0.37–1.59)。TIL存在与否在严重irAE终生风险或发生时间方面也无显著差异。
原发黑色素瘤或治疗前转移灶H&E切片的TIL评分与3级及以上irAE发生无关,TIL存在与irAE发生时间也无相关性。
The predictive value of tumor-infiltrating lymphocytes (TILs) in immune-related adverse event (irAE) development remains unknown, although an association between tumor immunogenicity and irAEs has been suggested. We investigated the association between TIL abundance in pretreatment primary and metastasis specimens and the subsequent development of severe irAEs.
We retrospectively identified patients with advanced cutaneous melanoma who received first-line anti-programmed cell death protein 1 (PD-1) with or without anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) from 10 hospitals in the Netherlands. TILs were scored on representative hematoxylin and eosin (H&E) stains of the primary melanoma and pretreatment melanoma metastasis as 'absent', 'nonbrisk', or 'brisk'. A univariable logistic regression analysis was carried out to assess the association between the TIL scores and the development of severe irAEs. Fine and Gray subdistribution hazard models were used to estimate the cumulative incidence of severe irAEs.
Of the 1346 eligible patients, 536 patients had primary melanoma specimens available, and 613 patients had metastasis specimens available. Severe irAEs occurred in 15% of anti-PD-1-treated patients and 49% of anti-PD-1 + anti-CTLA-4-treated patients. The presence of TILs was not associated with the occurrence of grade 3 irAEs in primary melanoma specimens ( P = 0.70) nor pretreatment metastasis specimens ( P = 0.91). In the univariable analysis, patients with brisk TILs did not have a higher chance of developing severe irAEs compared with patients with absent TILs, for both primary specimen (odds ratio 1.15, 95% confidence interval 0.60-2.18) and metastasis specimen (odds ratio 0.77, 95% confidence interval 0.37-1.59). There was also no significant difference in the lifetime risk or timing of the development of severe irAEs in patients with TILs present compared with patients with TILs absent.
There was no association between the TIL scores on H&E-stained slides from the primary melanoma or pretreatment metastasis and the development of grade 3 or higher irAEs. Additionally, no correlation was found between the presence of TILs and the timing of irAEs.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。